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The pattern recognition receptors of the innate immune
system are part of the first line of defence against
pathogens. However, they also have the ability to
respond to danger signals that are frequently elevated
during tissue damage and at sites of inflammation.
Inadvertent activation of pattern recognition receptors
has been proposed to contribute to the pathogenesis of
many conditions including inflammatory rheumatic
diseases. Prolonged inflammation most often results in
pain and damage to tissues. In particular, the Toll-like
receptors and nucleotide-binding oligomerisation
domain-like receptors that form inflammasomes have
been postulated as key contributors to the inflammation
observed in rheumatoid arthritis, osteoarthritis, gout and
systemic lupus erythematosus. As such, there is increasing
interest in targeting these receptors for therapeutic
treatment in the clinic. Here the role of pattern
recognition receptors in the pathogenesis of these
diseases is discussed, with an update on the development
of interventions to modulate the activity of these
potential therapeutic targets.Mammalian pattern recognition receptors
Innate immunity
The mammalian immune system consists of two effector
arms: the innate non-specific arm and the adaptive arm,
which recognises pathogens in an antigen-specific man-
ner. These two components of the immune system have
evolved to work in concert to provide a comprehensive
defence against a wide variety of pathogens, including
bacteria, viruses and fungi. The innate immune system
provides an immediate response in an effort to limit the
systemic spread of infectious agents. To do this the* Correspondence: s.sacre@bsms.ac.uk
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stated.receptors of the innate immune system need to be able to
identify a wide range of pathogens. This is made possible by
recognition of evolutionarily conserved pathogen-associated
molecular patterns (PAMPs) and as such these receptors
are termed pattern recognition receptors (PRRs) [1].
To enable comprehensive surveillance for pathogens,
PRRs are expressed as soluble receptors, on the cell sur-
face, in the cytosol and in the endosomal compartments
of cells (Table 1). The key functions of PRRs are to upreg-
ulate cell surface markers to trigger adaptive immunity
and to induce the expression and release of cytokines,
which activate tissue-resident macrophages and recruit
further immune cells to the site of infection. A similar re-
sponse occurs during many chronic inflammatory diseases
and tissue damage, where in a sterile inflammatory envir-
onment PRRs are activated by their ability to respond to
danger signals often referred to as ‘damage-associated mo-
lecular patterns’ (DAMPs) [2]. These are endogenous host
molecules that are released from stressed or dying cells or
that have formed crystals due to their presence in high
concentrations - for example, monosodium urate (MSU)
crystals in gout [3].The PRRs are able to recognise a diverse range of
PAMPs and DAMPS and are divided into five classes ac-
cording to their structural homology (Figure 1). The best
characterised in terms of known ligands, signalling path-
ways and functional biology are the Toll-like receptors
(TLRs) [4]. These are type I transmembrane receptors,
expressed either in the plasma membrane (TLR1, 2, 4, 5,
6, 10) or in the endosomal membrane (TLR3, 7, 8, 9).
TLRs can respond to a wide range of ligands that in-
clude proteins, lipopeptides and nucleic acids such as
single-stranded RNA, double-stranded RNA or CpG
DNA. Once activated, the TLRs engage adaptor mole-
cules to initiate downstream signalling pathways culmin-
ating in the activation of either interferon regulatoryThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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Table 1 Pattern recognition receptors associated with rheumatic disease
Pattern recognition receptor ligand(s) Association with rheumatic
Receptor Localization PAMPs DAMPs disease
TLRs
TLR2 Cell surface Lipoproteins Gp96 RA [37], OA [50]
Peptidoglycan Hyaluronan
Zymosan HMGB1
SNAPIN
TLR3 Endosome dsRNA DNA RA [24,30-32], OA [56]
TLR4 Cell surface LPS HSP70 RA [20,32,92], OA [42,43,48,50]
Envelope glycoproteins HMGB1
Mannan Hyaluronan
Fibronectin
Biglycan
TLR5 Cell surface Flagellin RA [34]
TLR7/8 Endosome ssRNA ssRNA RA [25-27], SLE [93,94]
TLR9 Endosome CpG DNA DNA OA [57], SLE [95]
NLRs
NOD1 Cytoplasm Diaminopimelic acid RA [39]
NLRP3 Cytoplasm RNA, DNA, MDP ATP Gout [3], RA [40], OA [59,60]
HA/uric acid crystals
Some examples of both exogenous (PAMPs) and endogenous (DAMPs) ligands are shown for each receptor. DAMP, danger-associated molecular pattern; dsRNA,
double-stranded RNA; HA, hyaluronic acid; HMGB-1, high mobility group box-1; LPS, lipopolysaccharide; HSP70, heat shock protein-70; MDP, muramyl dipeptide;
NLR, NOD-like receptor; NOD, nucleotide-binding oligomerization domain; OA, osteoarthritis; PAMP, pattern-associated molecular pattern; RA, rheumatoid arthritis;
SLE, systemic lupus erythematosus; SNAPIN, SNAP-associated protein; ssRNA, single-stranded RNA; TLR, Toll-like receptor.
Figure 1 Schematic representation of the major mammalian pattern recognition receptor families. Common to all Toll-like receptors (TLRs) are
leucine-rich repeats and a Toll-interleukin 1 receptor (TIR) domain. Nucleotide-binding oligomerization (NOD)-like receptors (NLRs) are characterised
by a central NOD domain and the defining feature of RIG-I-like receptors (RLRs) is a helicase domain. The two members of the recently described
AIM2-like receptors (ALRs) have HIN domains in common. The C-type lectin receptors (CLRs) are a very diverse group of proteins with no common
domain structure. The type I (DEC-205) and type II (DC-SIGN) transmembrane CLRs are represented here.
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The differential usage of the four adaptor proteins, myeloid
differentiation primary response 88 (MyD88), MyD88-
adapter-like (Mal), TIR-domain-containing adapter-inducing
interferon-β (TRIF) and TRIF-related adaptor molecule
(TRAM), determines which pathways are activated by in-
dividual TLRs [5].
Another family of primarily membrane bound PRRs
are the C-type lectin receptors (CLRs), some of which
exist as soluble receptors, such as the mannose-binding
lectin that activates the complement cascade. They are a
disparate family of receptors that bind to carbohydrate
structures in a calcium-dependant manner and are pos-
sibly the least well-characterised of the PRRs, in part
due to their sheer diversity. The membrane bound CLRs
exist as type I (for example, DEC-205 and the macro-
phage mannose receptor) or type II (Figure 1) trans-
membrane receptors (for example, dectin 1, dectin 2 and
DC-SIGN) [6]. These receptors have important roles in
antigen uptake and in modulation of innate immunity.
The remaining families of PRRs are intracellular,
expressed in the cytoplasm. The largest family are the
nucleotide-binding oligomerization domain (NOD)-like
receptors (NLRs), of which there are 22 in humans [7].
NLRs are further divided into subclasses (Figure 1), the
largest of which are the NLRCs, which contain a cas-
pase recruitment domain required to activate NF-kB,
and the NLRPs, which have a pyrin domain, which is es-
sential for the induction and regulation of the caspase-1-
inflammasome. A number of the NLRs are known to form
inflammasomes, but physiologically relevant roles have so
far only been shown for those formed by NLRP1, NLRP3,
NLRC4 and NAIP5, the most well characterised of which
is NLRP3. Upon activation, NLRP3 associates with its
adaptor protein apoptosis-associated speck-like protein
containing a caspase recruitment domain (ASC), and
caspase-1 to form a large oligomeric protein complex.
This leads to the activation of caspase-1, which can then
cleave pro-IL-1β and pro-IL-18 to their mature forms to
be released from the cell [8]. Activation of the NLRP3
inflammasome also results in pyroptosis releasing the
inflammasome complex as a speck from the cell into the
extracellular environment; specks can then be taken up by
neighbouring cells, further triggering activation of the
inflammasome in these cells [9].
The remaining classes of PRRs are cytosolic nucleic acid
sensors. The cytosolic retinoic acid-inducible gene-1 (RIG-
1)-like receptors are cytoplasmic RNA sensors; the family
is composed of RIG-1, melanoma differentiation associated
gene 5 (MDA5) and laboratory of genetics and physiology
2 (LGP2). Cytoplasmic DNA is recognised by the relatively
new family of PRRs, the absent-in-melanoma 2-like re-
ceptors (ALRs), consisting of four proteins in mammals:
gamma-interferon-inducible protein (IFI16), absent inmelanoma 2 (AIM2), myeloid cell nuclear differentiation
antigen (MNDA) and interferon-inducible protein X
(IFIX) [10]. They all share a HIN200 domain that confers
DNA-binding activity, as well as a pyrin domain that can
associate with other pyrin-containing proteins to enable
assembly of an inflammasome. However, only IFI16 and
AIM2 have so far been demonstrated to induce inflamma-
some formation. In addition to ALRs, other cytosolic
DNA sensors have been identified in recent years - for
example, cGAS, which can activate interferon (IFN) pro-
duction through activation of stimulator of IFN genes
(STING) [11].
The potential role of pattern recognition
receptors in inflammatory joint disease
A growing body of literature has suggested a role for in-
nate immune PRRs as key contributors to several chronic
inflammatory diseases where inflammation plays a major
role in maintaining the chronicity of the disease and ex-
acerbating the symptoms. In particular, TLRs and NLRs
have the potential to drive the chronic inflammatory com-
ponent of many arthritides, such as ankylosing spondylitis,
psoriatic arthritis, systemic lupus erythematosus (SLE)-
associated arthritis, rheumatoid arthritis (RA), osteoarth-
ritis (OA) and gout in a sterile setting. However, as our
knowledge of the other PRR families expands other fam-
ilies may also be found to be of importance. Consequently,
these receptors or their signalling pathways are being ex-
plored as novel therapeutic targets for RA, OA, gout and
SLE, which will be discussed in this review. A number of
therapeutics, including small molecules based on targeting
TLRs and NLRs, are already in development [12] (Table 2).
The NLRs are particularly amenable to targeting with
small molecule inhibitors due to the presence of the NOD
domain, an ATP-binding domain that may facilitate com-
petitive or allosteric inhibition.
Rheumatoid arthritis
RA is characterised by infiltration of inflammatory cells and
fibroblast proliferation in the synovial joints, leading to
chronic inflammation and a progressive destruction of bone
and cartilage [13]. The cells in the RA joint produce ele-
vated levels of cytokines, including TNF, IL-1 and IL-6, that
support Th17 cell differentiation and suppress the differen-
tiation of regulatory T lymphocytes, further perpetuating
the inflammatory environment [14]. The past decade has
seen the treatment of RA transformed by the use of bio-
logical therapies such as anti-TNF. Whilst a clear improve-
ment over conventional treatments such as methotrexate,
many patients fail to respond adequately to anti-TNF and
can become unresponsive to treatment over time. More re-
cently tociluzimab, an IL-6 receptor antibody, has shown
great promise in this patient group [15]. However, the
manufacturing cost of biological therapies remains a factor
Table 2 Developmental status of pattern recognition receptor antagonists for potential use as therapeutics
Compound Target Drug class Indications Company Clinical phase
NI-0101 TLR4 Antibody RA Novimmune Phase I
Chaperonin 10/X Toll TLR4 Protein RA, psoriasis, MS Cbio Ltd Phase II
VTX-763 TLR8 Small molecule Autoimmune disorders VentiRx Pharmaceuticals Pre-clinical
CRID3 NLRP3 Small molecule Amgen Pre-clinical
OPN-305 TLR2 Antibody Ischaemia reperfusion injury Opsona Therapeutics Phase I
IMO-3100 TLR7/TLR9 DNA-based small molecule Psoriasis Idera pharmaceuticals Phase II
DV1179 TLR7/TLR9 Small molecule SLE Dynavax Phase II
CPG52364 TLR7/TLR9 Small molecule SLE Pfizer Phase II
MS, multiple sclerosis; NLR, nucleotide-binding oligomerization domain-like receptor; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TLR,
Toll-like receptor.
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apies the disease reactivates in time, demonstrating that
cytokine blockade does not modify the upstream disease
mechanisms but instead works by dampening the resulting
inflammation.
The pathogenic mechanisms are still poorly under-
stood. There is increasing evidence from studies in both
human and animal models of RA that TLRs and NLRs
may contribute to this process [16,17]. Although it has
long been proposed that infection could play a role in
the initiation of RA, no specific pathogen has ever been
linked to disease. However, the identification of elevated
levels of endogenous PRR ligands, such as HMGB1, fi-
bronectin and, more recently, the heat shock protein
GP96, in the RA joint has highlighted the possibility that
activation of PRRs may play an important role in the
maintenance of inflammation in RA [18].
A variety of animal models have been used to identify
the potential roles of TLRs in RA with mixed results. IL-
1 receptor antagonist-deficient (IL-1Ra−/−) mice develop
spontaneous arthritis, but when crossed with TLR4−/−
mice, disease severity is reduced [19]. These results are
consistent with work from the same group demons-
trating that a naturally occurring TLR4 antagonist from
Bartonella Quintana had therapeutic effects in both the
IL-1Ra−/− model and the collagen-induced arthritis
(CIA) model [20]. Conversely, TLR2−/− mice crossed with
IL-1Ra−/− mice produced more severe arthritis, whilst
crossing with a TLR9−/− mouse had no effect on disease
[19]. In the IL-1Ra−/− mice TLR2 appears to be protective
whilst TLR4 is linked with disease development. However,
in a streptococcal cell wall-induced model of arthritis,
TLR2-deficient mice show a reduced disease severity,
highlighting the variability of results between arthritis
models [21].
Conflicting roles have also been reported for TLR3.
Activation of TLR3 suppressed arthritis in the mouse
CIA and K/BxN serum transfer models [22]. However,
TLR3 activation increased disease severity in the rat
pristane-induced arthritis and rat CIA models, whereupregulation of TLR3 was associated with disease and
downregulation via small interfering RNA improved
disease symptoms [23]. In a recent study, treatment of
pristane-induced arthritis rats with a miR-26a mimic de-
creased TLR3 expression and disease symptoms, con-
firming a role for TLR3 in this model [24]. TLR7 has
also been suggested to drive disease maintenance in the
rat CIA model where intra-articular knockdown of
TLR7 decreased disease activity [25]. In agreement with
this study, we found that although TLR7−/− CIA mice
developed arthritis symptoms, the disease did not pro-
gress, leading to a reduction in clinical score and paw
swelling compared with wild-type mice [26]. Together
these studies suggest the potential for a contribution
from TLRs to the maintenance of inflammation in arth-
ritis models. However, there are many conflicting animal
model studies in the literature, highlighting the need for
caution when interpreting these results in relation to hu-
man disease.
Many human studies have been conducted on synovial
tissue removed from patients during joint replacement
surgery. Human RA synovial tissue is composed of a
mixed population of cells, including RA synovial fibro-
blasts (RASFs), macrophages, T lymphocytes, B lympho-
cytes and dendritic cells, and has been demonstrated to
be auto-stimulatory in culture. Expression of most of the
TLRs has been demonstrated in the RA synovial mem-
brane. In our own studies, we have demonstrated that
activation of RA synovial membrane cultures with li-
gands for TLR1/2, 2/6, 3, and 4 and particularly TLR8
increased TNF production [27,28]. The major cell type
in the synovium is the RASFs expressing mainly TLR2,
3, 4 and 9, which on stimulation of TLR3 or 4 can pro-
mote Th1 and Th17 cell expansion [29]. Interestingly,
IL-17 has been reported to increase the expression of
TLR2, 3 and 4 in RASFs, creating the potential for a
positive feedback [30].
In comparison to OA tissue where there is a lower
level of inflammation, TLR2, 3, 4, 5, 7 and 9 are known
to be expressed at elevated levels in RA tissue [31-34].
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monocytes and correlates with disease activity [34]. In
addition to elevated expression of TLRs in the RA syno-
vium, we have previously demonstrated a functional role
for TLRs in generating inflammation in the RA syno-
vium from data generated using dominant negative ver-
sions of the TLR adaptor proteins MyD88 and Mal.
These dominant negative adaptor proteins prevent
downstream signalling and lead to a significant reduc-
tion in spontaneous cytokine and matrix metalloprotease
production from RA synovial membrane cultures [28].
Furthermore, we were also able to inhibit spontaneous
cytokine production from RA cultures by addition of
chloroquine or mianserin, both small molecule inhibi-
tors of the endosomal TLR3, 7, 8 and 9 [35]. Mianserin
is thought to inhibit TLRs via an off-target mechanism
and as such does not represent a suitable drug for clin-
ical trial; however, other inhibitors of the endosomal
TLRs are being developed for SLE, such as DV1179
(Dynavax, Berkeley, CA, USA) and CPG52364 (Pfizer,
New York, NY, USA), which may also be of therapeutic
benefit in RA (Table 2). Anti-malarials such as hydroxy-
chloroquine have long been used to treat RA and it is
believed that their effects are mediated through inhib-
ition of the endosomal TLRs. However, in clinical prac-
tice they are often given in combination with other
therapies as they cannot be used at high doses due to
ocular toxicity. Indeed, other anti-rheumatic agents trad-
itionally used in the treatment of RA have since been
shown to possibly work via modulation of TLR function.
For example, auranofin, an organogold compound, has
also been shown to inhibit TLR4 dimerization and TLR3-
dependent TRIF signalling [36]. Another approach to inhi-
biting TLR function in RA is by neutralising antibodies
(biologicals); Opsona Therapeutics (Dublin, Ireland) have
developed a TLR2 neutralising antibody which they have
shown can reduce spontaneous cytokine production from
RA synovial explants [37]. However, this antibody is cur-
rently in clinical trials for other conditions and not yet for
RA (Table 2). There are now several immune modulators
at various stages of development that target TLRs with a
potential role in RA (Table 2); though as yet none have
been approved for use in the clinic.
In addition to TLRs, evidence is emerging that the
NLRs may also have a role and could also represent po-
tential therapeutic targets for RA [38]. Both NOD1 and
NOD2 are expressed in synovial tissue and expression of
NOD1 is increased in RA synovium compared with OA
[17]. Silencing of NOD1 in RASFs decreased TLR2- and
IL-1β-induced IL-6 production, suggesting that NOD1
can synergize with TLRs in potentiating inflammation in
RA [39]. More recently, the NLRP3 inflammasome has
been implicated in a murine model of RA, where dele-
tion of A20 triggers spontaneous erosive polyarthritisthrough an increase in NLRP3 activation [40]. Several
inhibitors of the NLRP3 inflammasome are currently in
preclinical development and will be discussed below in
more detail in relation to gout.
Osteoarthritis
OA is the most common form of arthritis and a leading
cause of musculoskeletal pain and disability worldwide.
The normal balance of the turnover of articular matrix
is upset, with a loss of collagen and aggrecan, which is
due in part to the activity of aggrecanases and the colla-
genase MMP-13 [41]. However, the complex pathogen-
esis of OA is poorly understood and consequently there
is a lack of clinically effective treatments, which means
that many patients eventually go on to have joint re-
placement surgery. Until recently, OA was considered to
be a disease primarily affecting cartilage and bone. How-
ever, synovitis is increasingly considered to be an im-
portant process in the pathogenesis, albeit at a much
lower level than observed in RA. In OA patients, syn-
ovial inflammation has been associated with higher pain
scores and more rapid destruction of cartilage [41].
Similar to RA, many endogenous molecules are pre-
sent in the OA joint where they are suggested to func-
tion as DAMPs that can activate PRRs. These molecules
are possibly released due to trauma and age (both strong
risk factors for OA) or as a result of synovial and cartil-
age catabolism [42-44]. Obesity is another strong risk
factor for OA and is associated with increased circulat-
ing levels of free fatty acids. The saturated free fatty acid
palmitate can activate TLR4, and in synergy with IL-1β
can induce chondrocyte death, release of IL-6 and extra-
cellular matrix degradation [45]. Higher levels of TLR
DAMPs such as tenascin C, HMGB1, fibrinogen and fi-
bronectin isoforms have been observed in OA synovial
fluid and tissue samples [46-48]. Furthermore, fibrin, the
cleaved form of fibrinogen, has been associated with
disease severity in OA [49]. In addition to the presence
of DAMPs, synovial fluid from patients with early OA
has been shown to augment the responses of TLR2 and
TLR4 in fibroblast-like synoviocytes through the provision
of increased levels of the TLR accessory molecule CD14
[50]. CD14 is also suggested to act as an accessory mol-
ecule for TLR3, 7, 8 and 9, leaving the possibility that acti-
vation of other TLRs could also be amplified in OA joint
tissue [51,52].
A variety of TLRs are expressed in cells within the
joint. Articular chondrocytes express TLR1-9 at the
mRNA level [53] and the proportion of cells expressing
TLRs in the cartilage has been observed to increase with
the grade of OA lesion [54]. TLR2, 3, 4 and 7 have also
been detected in the synovium in OA [41,55]. Further-
more, functional polymorphisms in the promoters of
TLR3 (rs3775296) and TLR9 (−1486 T/C) have been
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populations [56,57].
However, most studies have focused on TLR2 and 4 as
most of the DAMPs identified are ligands for these re-
ceptors. TLR-deficient animal models of OA have given
mixed results. In the collagenase-induced mouse model,
TLR2 knockout increased the degree of OA, whereas in
the destabilised medial meniscus model TLR2 deficiency
did not affect the extent of disease [46]. In the medial
meniscectomy model, dual knockout of both TLR2 and
TLR4 offered only mild protection [46]. Furthermore, in
the knee menisectomy model, TLR1, 2, 4 or 6 knockout
or knockout of the TLR adaptor molecule MyD88 had
no effect [58]. It is important to note that several of
these models are not associated with significant synovitis
or inflammation and thus may not accurately reflect the
human form of disease.
In addition to TLRs, there may also be a role for crystal-
induced activation of the inflammasome. The deposition
of hydroxyapatite (HA) crystals occurs in around 60% of
OA patients, and correlates with severity of cartilage deg-
radation [59]. HA crystals have been shown to stimulate
secretion of IL-1β and IL-18 from murine macrophages in
a NLRP3 inflammasome-dependent manner [60]. IL-1β in
turn promotes synovial inflammation and cartilage degen-
eration, with elevated IL-18 in the cartilage and synovial
fluid known to correlate with OA disease severity [60].
ANK-deficient mice can be used as a model of HA crystal-
induced arthritis; they have a spontaneous mutation in the
ank gene resulting in deposition of HA crystals in synovial
fluid and articular cartilage causing cartilage erosion and
joint immobility [61]. NLRP3-deficient ANK−/− mice ex-
hibit decreased degeneration of cartilage as well as joint
inflammation, suggesting a central role for the NLRP3
inflammasome in the pathogenesis of OA where HA crys-
tals are evident [60].
Based on these observations, inhibition of IL-1β would
seem to be an attractive therapeutic for OA, particularly
as recombinant IL-1Ra (anakinra), a competitive inhibi-
tor of the IL-1 receptor, and an anti-IL-1β monoclonal
antibody (canakinumab) are already licensed for use in
the clinic. Disappointingly, intra-articular injection of
anakinra failed to produce any therapeutic benefit above
that of placebo [62]. However, a small study involving
just three patients with erosive OA has demonstrated
clinical benefits after 3 months of daily subcutaneous
anakinra injections [63]. It may be that IL-1 blockade
has a place in some clinical subtypes of OA or may re-
quire combination with other therapies to be fully effect-
ive, but larger studies would need to be performed to
determine this. Whilst there appears to be a potential
role for TLRs and NLRP3 in the generation of the in-
flammation associated with OA, research in this area re-
mains in its infancy. However, until there is a clear ideaof which PRRs are of importance and the contribution
that they make to the pathology of OA, it is unlikely that
any of these inhibitors will be specifically investigated in
the context of OA. Currently the treatment of OA lacks
effective disease-modifying drugs, instead relying on
nonsteroidal anti-inflammatory drugs to provide pain re-
lief. PRRs may provide novel therapeutic targets in the
future if a contribution to OA pathogenesis can be
confirmed.
Gout
Another form of arthritis associated with the production
of IL-1β is gout. This is an inflammatory arthritis caused
by precipitation of MSU crystals in the joint. It is distin-
guished from RA and OA by the clinical presentation of
acute inflammatory monoarthritis, typically affecting the
metatarsophalangeal joint. A defining feature of gout is
acute inflammatory flares that develop very rapidly, reach-
ing a peak 6 to 24 hours after onset, followed by spontan-
eous resolution within 4 to 14 days [64]. In the absence of
effective long-term treatment, these recurrent acute at-
tacks can progress to chronic disease resulting in an ero-
sive polyarthritis [64]. Although a role for MSU in gout
has been recognized for centuries, the mechanisms by
which MSU crystals trigger the pain and inflammation of
an acute gout attack have only more recently been unrav-
elled. There is now compelling evidence implicating IL-1β
as a key mediator of inflammation in gout, which in turn
promotes the influx of neutrophils into the synovium and
joint fluid [65]. The discovery of the inflammasome pro-
pelled forward the understanding of the pathogenesis of
gout, with the importance of the NLRP3 inflammasome
now well established. It has been demonstrated that MSU
crystals are taken up by cells, triggering the assembly of
the NLRP3 inflammasome and subsequent production of
IL-1β [3]. This was confirmed using macrophages from
mice deficient in the inflammasome components caspase
1, ASC or NLRP3 which failed to activate IL-1β in re-
sponse to stimulation with MSU crystals [3]. More re-
cently, the CLR Clec12a (also known as myeloid inhibitory
C-type lectin-like receptor) has been identified as a recep-
tor for MSU in human neutrophils. The role of this CLR
in sterile inflammation appears to be one of negative regu-
lation of the neutrophil-mediated inflammatory response
[66,67]. Knockdown of Clec12a in a human neutrophil cell
line resulted in enhanced IL-8 production and Ca2+ signal-
ling and Clec12a knockout mice showed increased neutro-
phil influx in response to MSU crystals. However, it is
interesting to note that Clec12a signalling does not affect
the NLRP3 inflammasome pathway [67], so this CLR is an
unlikely target for gout therapy.
Treatment for gout has remained unchanged for de-
cades. Non-steroidal anti-inflammatory drugs remain the
first line of treatment, followed by glucocorticoids. The
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decreasing the production of uric acid by inhibition of
the enzyme xanthine oxidase [68]. Two inhibitors of
xanthine oxidase, febuxstat and allopurinol, are licensed
for clinical use. In addition, oral colchicine, which sup-
presses MSU crystal-induced inflammasome assembly,
has been used clinically for many years, long before the
discovery of the NLRs. It is very effective in treating
gout, but is poorly tolerated due to gastrointestinal side
effects. The mechanisms of action of colchicine are still
being elucidated, but it is known to have effects on
Clec12a and NLRP3. Neutrophil adhesion and che-
motaxis are inhibited via maintenance of Clec12a ex-
pression and inflammasome formation is blocked by
prevention of ASC association with NLRP3 due to its ef-
fects on microtubule formation [66,69]. In recent years,
with the advent of biological therapies such as anakinra,
rilonacept (soluble IL-1 receptor) and canakinumab, re-
search has focused on blocking IL-1β as a means of con-
trolling the symptoms of gout. Early clinical studies of
these IL-1 inhibitors demonstrated good efficacy and
high tolerance [70], although an increased risk of infec-
tion caused by blockade of pro-inflammatory cytokines
remains a consideration, together with the high cost of
these biological therapies. A desirable alternative would
be a small molecular weight inhibitor of NLRP3. A num-
ber of small-molecule compounds that inhibit activation
of NLRP3 have been developed, including glyburide (al-
beit at high doses), parthenolide, Bay11-7082 and cyto-
kine release inhibitory drug 3 (CRID3) [71,72]. However,
with the exception of glyburide, which is used to treat
type 2 diabetes, these compounds are still in preclinical
testing.Systemic lupus erythematosus
SLE is a systemic autoimmune disease that involves most
organs of the body, with a wide range of clinical manifes-
tations, including arthritis, nephritis, skin rash, anaemia
and lymphopenia [73]. It is characterised by B-cell auto-
immunity, particularly to nucleic acids and their binding
proteins, which in part arises due to defective clearance of
apoptotic cells [74,75]. Phagocytosis of DNA and RNA im-
mune complexes via Fcγ receptors leads to activation of
PRRs and, in particular, TLR7 and 9 as they recognize
RNA and DNA, respectively [76,77]. In fact, TLR7 and 9
are robust activators of B cells and dendritic cells stimulat-
ing autoantibody production and IFN-α, which are both
characteristic of SLE [78,79]. IFN-α plays a critical role in
the severity and progression of SLE [80]. A high percent-
age of SLE patients (in the order of 95% of children and
70% of adults [81]) have an ‘IFN signature’, which refers to
the higher expression of many IFN-inducible genes in
these patients.Other cytoplasmic PRRs involved in the antiviral re-
sponse have also been linked to SLE. Variants of the
RIG-1-like receptor MDA5 have been associated with
apoptosis, inflammation and autoantibody production
and with increased susceptibility to SLE [82]. Thus, it is
likely that multiple pathways of nucleic acid recognition
are involved in the generation of IFN-α. Supporting evi-
dence from the literature include a role for the PRRs
AIM2 and DNA-dependent activator of IRFs (DAI). DAI
was reported to be increased in both SLE patients and
murine models of disease, whilst AIM2 correlated with
disease severity [83,84]. In agreement with these data,
AIM2-deficient mice demonstrate decreased susceptibil-
ity to lupus-like disease in murine models, via inhibition
of macrophage activation and secretion of proinflamma-
tory cytokines [83].
The importance of NLRs in the pathogenesis of SLE is
less clear. Although some NLRs (for example, NLRP3)
have been associated with immune responses to DNA,
the downstream cytokines generated by activation of
these receptors are IL-1β and IL-18. Although both of
these cytokines are pro-inflammatory and can activate
macrophages, neutrophils and T cells, they have not
been directly implicated in SLE. At present, therefore,
the most relevant of the PRRs for therapeutic targeting
in SLE remain the TLRs because of the current pre-
clinical and clinical evidence of their roles in SLE, as
well as the existence of a number of small molecular
weight antagonists currently in development.
Quinine-containing compounds have been used in the
treatment of SLE for some time. These drugs prevent
acidification and maturation of the endosome, thereby
blocking TLR signalling as acidification is a prerequisite
for endosomal TLR activation [85]. The efficacy of this
treatment [86] thus provides further indication of the in-
volvement of TLRs in the pathogenesis of SLE and justi-
fies the on-going research efforts in developing new
therapies based on targeting TLR7 and 9. As shown in
Table 2, a number of therapeutics that target endosomal
TLRs are at various stages of development for the treat-
ment of SLE. This approach, based on blocking TLR7-
and 9-induced IFNα, may make patients less prone to
infections than global direct suppression of IFN-α using
neutralising antibodies, and so may provide a better
therapeutic strategy.
Conclusion
There is a clear potential for targeting TLRs and NLRs
for the treatment of inflammatory rheumatic diseases
such as RA, OA, gout and SLE. Although these recep-
tors have a key role in the defence against pathogens, re-
dundancy between the families may permit therapeutic
inhibition of some receptors without having to signifi-
cantly compromise innate immune defences. It is
Mullen et al. Arthritis Research & Therapy  (2015) 17:122 Page 8 of 10promising to note that MyD88-deficient patients (that
have lost signalling from all of the TLRs apart from
TLR3), although susceptible to a number of pyogenic
bacteria, showed normal resistance to most infections
[87]. Thus, partial inhibition of a single receptor or
group of receptors may not have a significant effect on
immunity.
There is also the possibility that longer term inhibition
of PRRs could have a negative impact on tissue remodel-
ling and repair. TLRs in particular have roles in tissue
repair and regeneration after tissue injury [88]. There
are little available data on the roles of TLRs in tissue re-
pair in the context of arthritic joints, but the importance
of TLRs in tissue regeneration has been demonstrated in
the lung [89], liver [90] and colon [91]. Once the import-
ance of TLRs in joint tissue remodelling and repair be-
comes clear, it may be possible to adjust the timing and
selectivity of therapeutics accordingly.
For gout the role of the NLRP3 inflammasome has
been clearly defined and it will be of great interest to fol-
low the development of NLRP3 inhibitors such as
CRID3 that have the capability to be of significant clin-
ical benefit during disease flares. The involvement of
PRRs in the pathogenesis of OA is much less clear, with
further research required to determine which PRRs are
of importance. For RA there are encouraging data from
both mouse models and human studies suggesting a po-
tential role for TLRs, and in particular the endosomal
TLRs in disease maintenance. Targeting the endosomal
TLRs is particularly attractive as these receptors are
amenable to modulation by small molecular weight
compounds which could present a much cheaper alter-
native to the anti-cytokine biological therapies currently
used in the treatment of RA.
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